Antagonist Binding
Antagonist Binding - Related Videos
01:24
Cholinergic Antagonists: Pharmacokinetics
0 Views •
2023
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and the conjunctiva.
06:27
Competitive Binding Assay to Identify Compounds Disrupting Receptor-Ligand Interactions
0 Views •
2025
In this video, we describe a flow cytometry-based competitive binding assay to detect the interactions between the CXC Chemokine Receptor 4 (CXCR4) and its fluorescently-labeled natural ligand CXC Chemokine Ligand 12 (CXCL12), in the presence of a CXCR4-targeting small molecule. Incubating CXCR4-expressing cells with lower small molecule concentrations allows CXCR4-CXCL12 binding to some extent, which progressively declines upon a gradual increase in small molecule concentrations.
02:18
The Equilibrium Binding Constant and Binding Strength
0 Views •
2020
The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium: where P and L are the unbound protein and ligand, respectively, and PL is the protein-ligand complex. As the amount of bound ligand is also related to the rate of ligand binding, experiments can also determine Kb by examining the rates of protein-ligand association (kon) and dissociation (koff) using the following ratio: Thus,...
01:26
Cholinergic Antagonists: Therapeutic Uses
0 Views •
2023
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics: Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...
01:28
Cholinergic Antagonists: Pharmacological Actions
0 Views •
2023
Antimuscarinic drugs block muscarinic receptors in multiple systems, including the gut, eye, smooth muscles, respiratory tract, cardiovascular, and central nervous systems. They produce similar effects with varying selectivity depending on the specific agent and tissue. Here are the key pharmacological actions of antimuscarinics: Gastrointestinal Effects: Antimuscarinics reduce gut contractions, increase gastric emptying, and slow intestinal transit. They partly inhibit gastric acid secretion...
FAQs
Affinity describes how strongly an antagonist interacts with its receptor, while receptor occupancy indicates how many receptors are engaged at a given condition. Reversibility determines whether that interaction can be released. Considering these properties together helps pharmacologists relate molecular binding behavior to the extent and persistence of agonist-response blockade.
The binding site helps determine how an antagonist modifies receptor function. Orthosteric antagonists occupy the site normally used by an agonist and prevent access there, whereas allosteric antagonists bind elsewhere and alter receptor activity. This distinction gives researchers a mechanistic basis for comparing how different ligands regulate receptor signaling.
Researchers compare antagonist effects with agonist dose-response behavior and examine how the response changes as antagonist conditions vary. Dose-response curve interpretation can reveal whether the antagonist acts through competition at the receptor or through a noncompetitive mechanism. This analysis connects observed pharmacological responses with the underlying interaction between agonist, antagonist, and receptor.
A study can relate antagonist affinity, receptor occupancy, and reversibility to changes in agonist-induced responses. Researchers may then interpret dose-response curves to connect binding behavior with functional effects. Considering binding and response together is important because receptor interaction alone does not fully describe how signaling pathways are modified by a drug.
Antagonist binding information is useful when researchers need to regulate excessive or unwanted physiological responses. Comparing affinity, occupancy, binding site, and reversibility can help characterize how candidate drugs interact with receptors. These findings support therapeutic design by linking molecular receptor behavior to the intended control of biological signaling.
By preventing an agonist response or altering receptor activity, an antagonist provides a way to examine how receptor engagement influences downstream signaling. Pharmacologists can compare dose-response behavior and binding characteristics to determine how a drug modifies that pathway. This context helps explain drug action and guides optimization of treatments that regulate physiological responses.